Tubulis
Tubulis is a biotechnology company developing antibody-drug conjugates (ADCs), including its advanced candidates TUB-040 and TUB-030, for targeted therapy.
Secondary Market Price
How Tubulis Measures Up
To help you manage your Tubulis equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Tubulis's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Tubulis Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Tubulis's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Tubulis is a biopharmaceutical company headquartered in Munich, Germany, that develops antibody-drug conjugates (ADCs) to treat cancer and other serious illnesses. The company combines its proprietary technologies with disease-specific biology to create protein-drug conjugates. Its work involves advancing its own pipeline of drug candidates and providing development solutions for partners. Founded in 2012 by individuals including current CEO Dominik Schumacher and CSO Jonas Helma-Smets, Tubulis focuses on expanding the therapeutic applications of ADCs.
The company is advancing its two most developed ADC candidates, TUB-040 and TUB-030, into later-stage clinical evaluation, having already released initial clinical data for TUB-040. In late 2025, Tubulis raised US$358.1 million in a Series C financing round. The company also recently appointed Charles Fuchs as Chief Medical Officer to guide its clinical strategy. A collaboration with Gilead Sciences earned Tubulis a 'Deal of the Year' award at the European Lifestars Awards, and the company was recognized by WirtschaftsWoche as one of 30 pioneers shaping Germany's future.
- Venrock Healthcare Capital Partners
- Wellington Management
- Ascenta Capital
- Nextech Invest
- EQT Life Sciences
- Frazier Life Sciences
- Andera Partners
- Deep Track Capital
- Bayern Kapital
- Fund+
- High-Tech Gründerfonds (HTGF)
- OCCIDENT
- Seventure Partners
- Fidelity Management & Research Company
- Janus Henderson Investors
- Blackstone Multi-Asset Investing
- Co-Founder, Dominik Schumacher
- Co-Founder, Jonas Helma-Smets
- Co-Founder, Christian Hackenberger
- Co-Founder, Heinrich Leonhardt
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Tubulis worth joining?
Whether joining Tubulis is a good move depends on your personal career goals and how you evaluate the company's overall compensation package, including its equity. A platform like Prospect can help you analyze the potential future value of your equity stake to make a more informed decision.
What should I do with my Tubulis stock?
Deciding what to do with your private company stock involves complex financial and tax considerations that are unique to your personal situation. Tools from Prospect can provide personalized strategies for exercising options, planning for taxes, and maximizing the value of your holdings.
Can you sell Tubulis stock?
Selling stock in a private company like Tubulis is typically possible during specific liquidity events, such as company-approved tender offers or on secondary markets. Platforms like Prospect offer tools to help you navigate these opportunities and determine the most tax-efficient way to sell your shares.
How can I find the value of my Tubulis stock?
The official value of private stock is determined by a 409A valuation, but forecasting its future potential requires more sophisticated analysis. You can use Prospect’s predictive models, which are trained on venture capital data, to project the potential future worth of your equity.
What is Tubulis's equity worth?
The current worth of Tubulis equity is based on its most recent 409A valuation, which sets the fair market value for tax and compliance purposes. To understand what your equity could be worth in the future, you can use platforms like Prospect to model different scenarios and project potential growth.
What is Tubulis's stock ticker symbol?
As a private company, Tubulis is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are assigned only when a company completes an Initial Public Offering (IPO) and lists its shares for public trading.
Can I buy or sell Tubulis stock?
Selling private shares is often possible through company-approved tender offers, while buying is typically restricted to accredited investors during financing rounds. If you are an employee or existing investor looking to sell, Prospect provides tools to help you make tax-optimized decisions during liquidity events.
What is the criteria to buy or invest in Tubulis stock?
Investing in a private company like Tubulis is generally limited to institutional investors or individuals who meet the SEC's criteria for being an accredited investor. Employees may also receive equity as part of their compensation package without needing to meet these financial thresholds.
